Journals / Selçuk Tıp Dergisi / 2022 / Cilt: 38 - Sayı: 1

Rare Mutation in Androjen Receptor Gene with a Case of Primary Amonerrhoea

Pages
53–57
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

So, we thought that the mutation may cause a physical defect in protein and the native three-dimensional structure of the AR gene

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Androgen insensitivity syndrome (AIS) is an X-linked recessive disorder associated with incompatible genotypes and phenotypes caused by mutations in the androgen receptor (AR) gene is located at Xq11-q12.
📊
Key Findings & Data:Clinical findings are female external genitalia at birth, abnormal secondary sexual development in puberty, infertility in individuals with a 46, XY karyotype as typically characterized AIS.
💡
Conclusion & Impact:So, we thought that the mutation may cause a physical defect in protein and the native three-dimensional structure of the AR gene
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Androgen insensitivity syndrome (AIS) is an X-linked recessive disorder associated with incompatible genotypes and phenotypes caused by mutations in the androgen receptor (AR) gene is located at Xq11-q12. We have detected a rare mutation in the AR gene that has not been reported in the literatüre. Clinical findings are female external genitalia at birth, abnormal secondary sexual development in puberty, infertility in individuals with a 46, XY karyotype as typically characterized AIS. In our case, a 17-yearold female phenotype presented with primary amenorrhoea and predominantly female external genitalia. The patient had 46,XY with female phenotype. We detected a missense rare mutation in the first exon as NM000044 c.5A>G variant was not found in ExAc or 1000genome population database. Substituting at position 2 to glutamic acid exchange to glycine. Glutamic acid is a polar amino acid with a negative charge while glycine has stayed in a nonpolar hydrophobic group. So, we thought that the mutation may cause a physical defect in protein and the native three-dimensional structure of the AR gene

🔖

Cite This Article

GÖKTAŞ, E., ZAMANI, A. G., YILDIRIM, M. S., SOMUNCU, M. N., GEZGİNÇ, K. (2022). Rare Mutation in Androjen Receptor Gene with a Case of Primary Amonerrhoea. Selçuk Tıp Dergisi, Cilt: 38 - Sayı: 1, 53–57. https://ajindex.com/articles/591756

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in globocan 2012. Int J Cancer 2015; 136(5): E359- 86
  2. Che K, Zhao Y, Qu X, et al. Prognostic significance of tumor budding and single cell invasion in gastric adenocarcinoma. Onco Targets Ther 2017;10:1039-47
  3. Lauren P. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49
  4. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumors of the Digestive System. In: Lauwers GY, Carneiro F, Graham DY, (Eds). Tumors of the Stomach. Lyon: IARC, 2010;45-63
  5. Ueno H, Murphy J, Jass JR et al. Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 2002; 40(2): 127-32
  6. Mitrovic B, Schaeffer DF, Riddell RH et al. Tumor budding in colorectal carcinoma: Time to take notice. Mod Pathol 2012;25(10):1315-25
  7. Wang LM, Kevans D, Mulcahy H, et al. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 2009; 33(1): 134-41
  8. Lugli A, Karamitopoulou E, Zlobec I. Tumour budding: A promising parameter in colorectal cancer. Br J Cancer 2012;106(11):1713-7
  9. De Smedt L, Palmans S, Sagaert X. Tumour budding in colorectal cancer: What do we know and what can we do? Virchows Arch 2016;468(4):397-408
  10. Yamaguchi Y, Ishii G, Kojima M, et al. Histopathologic features of the tumor budding in adenocarcinoma of the lung: Tumor budding as an index to predict the potential aggressiveness. J Thorac Oncol 2010;5(9):1361-8
  11. Ohike N, Coban I, Kim GE, et al. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol 2010;34(10):1417-24
  12. Brown M, Sillah K, Griffiths EA, et al. Tumour budding and a low host inflammatory response are associated with a poor prognosis in oesophageal and gastro-oesophageal junction cancers. Histopathology 2010; 56(7): 893-9
  13. Haisma MS, Plaat BEC, Bijl HP, et al. Multivariate analysis of potential risk factors for lymph node metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J Am Acad Dermatol 2016;75(4):722-30
  14. O'Connor K, Li-Chang HH, Kalloger SE, et al. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma. Am J Surg Pathol 2015;39(4):472-8